Amid complaints about unilateral drug company restrictions on the 340B drug pricing program and mounting pressure from industry-backed advocates for even more 340B changes to favor drugmakers, a bipartisan group of six U.S. senators have taken a proactive step by asking for ideas to ensure “stability” for 340B. This move came in the form of a request for information (RFI) … [Read more...]
Senate Report Blasts Insulin Makers for High Prices
January 21, 2021– A new, bipartisan report from a key congressional committee is sharply critical of the three major drug manufacturers that sell insulin in the U.S. The companies – Eli Lilly, Novo Nordisk, and Sanofi – already have been all over the news recently for their pricing behavior. They also are the ringleaders of a group of drug companies that are circumventing … [Read more...]
Bipartisan Bill Would Protect 340B Status During Emergency
July 8, 2020— New bipartisan legislation introduced by six senior members of the U.S. Senate would protect hospitals from losing eligibility for the 340B drug pricing program during the COVID-19 health emergency. The bill (S. 4160) was introduced July 2 by Sen. John Thune (R-S.D.), the majority whip and second-ranking member in the Senate. Thune was joined by five original … [Read more...]
House E&C Oversight Subcommittee 340B Hearing Recap
October 11, 2017—The House Energy & Commerce oversight subcommittee held its second hearing on the 340B program this morning, focusing on how covered entities track and use their savings to improve patient care. Three 340B hospitals and health systems testified – Mission Health (N.C.), The Johns Hopkins Hospital (Md.), and Northside Hospital (Ga.). The committee also heard … [Read more...]